Angela
Even though many novel targeted therapies for B-cell malignancies have been introduced to the market, many cases of B-cell malignancies still are resistant to treatment or progress despite therapy with single agents of BTK-inhibitors. Development of novel BTK-inhibitors as well as optimization of treatment strategies and combination regimens are being investigated in clinical research.
A new approach in the treatment of B-cell malignancies is BTK-targeted protein degradation. Tacabrutideg (BGB-16673) is an investigational small molecule BTK-targeted protein degrader currently studied in several clinical trials. As a novel treatment approach for patients with B-cell malignancies, Tacabrutideg should be considered an investigational therapeutic agent and not as an established or approved treatment for patients with B-cell malignancies.
Understanding the Rationale for BTK Degradation
BTK is a critical component in the B-cell receptor signaling pathway controlling important cellular processes of B-cells including proliferation, survival, migration, and the tumor environment. Inhibitors of BTK, whether covalent or non-covalent, bind to one of the BTK kinase domains and inhibit the enzymatic activity.
The main difference between how a protein degrader works and a typical drug is that a protein degrader aims to degrade the protein of interest rather than inhibit the protein’s activity. In the case of BTK, there is a new BTK-targeted protein degrader currently in early phase clinical trials for the treatment of B-cell malignancies. The drug is called Tacabrutideg and is known by the developmental code named BGB-16673.
The protein degradation approach seeks to remove BTK from cells rather than stop BTK’s enzymatic activity. The clinical relevance of this distinction regarding altered BTK in the setting of resistance to covalent inhibitors remains to be addressed in clinical trials.
Development in Relapsed and Refractory Disease
The initial clinical trials of Tacabrutideg are enrolling patients with relapsed and/or refractory B-cell malignancies. The CaDAnCe-101 Phase 1/2 dose-escalation study of Tacabrutideg is designed to investigate Tacabrutideg in patients with CLL/SLL, MCL, MMZL, FL, WM and other B-cell malignancies.
The rationale for the investigation of Tacabrutideg in heavily pretreated patient populations with relapsed/refractory B-cell malignancies is like other emerging therapeutic agents in hematology. However, in each treatment era, there are significant differences in the mechanisms of action of therapeutic agents as well as their resistance profiles.
Most data were presented from a study in relapsed/refractory patients with a median of four prior therapies. Updated data from this Phase 1 study were presented in 2026 for CLL/SLL patients and demonstrated safety/tolerability as well as antitumor activity but further clinical development is required to determine its appropriate use in patients with B-cell malignancies.
Tacabrutideg and CLL/SLL
CLL/SLL is one of the many malignancies that are being investigated as part of the Tacabrutideg clinical development program. The Phase 3 CaDAnCe-103 randomized study compares Tacabrutideg to Pirtobrutinib in adults with CLL/SLL and previously treated with covalent BTK inhibitor(s).
Another Phase 3 trial of Tacabrutideg is planned, comparing the agent against investigator’s choice in patients with CLL/SLL that are previously exposed to both a BTK inhibitor and a BCL2 inhibitor and have relapsed on these therapies. These patients may need additional treatment options.
It is also important to note that early activity in a very treatment advanced patient population does not necessarily translate into comparative clinical benefit over current therapies. Furthermore, to assess true comparative benefit of a new agent, randomized studies vs current standard of care are typically required.
Broader Applications in B-Cell Malignancies
There are additional diseases under investigation in combination with other agents in patients with relapsed or refractory B-cell malignancies. This program also includes multiple cancers including MCL, FL, MZL, WM and DLBCL.
The broader development of Tacabrutideg and its clinical utility in different B-cell malignancies is an area of active investigation given the involvement of BTK signaling in these diseases. Each disease, however, has distinct biology and has different treatment standards and unmet clinical needs, thus results in one disease cannot automatically be translated to another.
This agent has also received FDA orphan-drug designation for Follicular Lymphoma and Mantle Cell Lymphoma, but such designation does not confer approval for the use of Tacabrutideg for these diseases.
Combination Strategies and Future Research
Tacabrutideg is being investigated in a Phase 1/2 master trial in combination with the following targeted therapies: Sonrotoclax, Zanubrutinib, Mosunetuzumab, and Glofitamab. Prospective clinical trials are needed to assess the safety profile, dosing, potential drug interactions, and clinical activity of combination regimens that include Tacabrutideg.
Safety and Evidence-Based Clinical Practice
A comprehensive description of adverse events (including treatment-emergent adverse events) and higher-grade events for Tacabrutideg is provided in early data, but continued evaluation of the safety profile of the drug is needed to provide insights on the use of the drug in a larger and more diverse population of patients.
The role of investigational agents, including Tacabrutideg, in the management of relapsed or refractory B-cell malignancies continues to be evaluated in clinical trials, while approved therapies remain the standard of care.
The Evolving Role of BTK-Targeted Therapy
The development of Tacabrutideg and other targeted protein degradation approaches is an area of ongoing research in hematology to treat BTK-driven malignancies and overcome resistance mechanisms to previously covalent BTK inhibitors. The potential clinical role of this investigational BTK protein degrader in patients with refractory B-cell malignancies continues to be evaluated in clinical trials.
Medical Disclaimer: The information provided in this article is intended for educational purposes only and should not be interpreted as medical advice, clinical guidelines, or a recommendation for any specific treatment.
Read More at USA Times
